The media and tubes can be decontaminated in or with 10% bleach and discarded as normal.
Yes, probably the patient would be taking some form of drug treatment when we look at the progression-free survival graph. Basically, the patients were not treatment free at the time.
Our models don't differentiate between different types of dosing, so they can be viewed as outcomes for standard clinical practice. For instance, if MTD is more common in practice, the models may more closely reflect MTD.
Currently, our services are for canine lymphoma and leukemia. We will be expanding our services to other species and other blood / lymphoid cancers in the near future.
PARR, which stands for PCR for Antigen Receptor Rearrangements, is used to discriminate between lymphoma/leukemia and reactive/inflammatory conditions when cytology is equivocal. Our canine PARR assay detects the expansion of B-cell cancer clones by amplifying the VJ region of the immunoglobulin heavy chain gene (IgH) and detects the expansion of T-cell cancer clones by amplifying a region in the T-cell receptor gamma chain gene.
The more samples ImpriMed processes and the more clinical outcomes we receive from our customers, the more accurately our AI models are able to determine which drugs will work best for your patients. (Click to read more)
